Superinfections in patients treated with teicoplanin as anti SARSCoV2 AGENT

We read with interest the paper by Giacobbe et al. estimating a cumulative risk of developing at least one bloodstream infection (BSI) episode (largely due to Gram-positive pathogens) of almost 50% after 30 days at risk in (2) Similarly, Somers et al. reported an increased risk to develop bacterial superinfections, principally represented by Staphylococcus aureus ventilatory associated pneumonia (VAP), in critically ill patients infected with SARS-CoV-2 and treated with Tocilizumab. (1) We previously described a cohort of intubated patients affected by severe COVID-19pneumonia treated with the best available therapy (BAT), including Tocilizumab and associated with Teicoplanin. (3) This glycopeptide antibiotic was used with a double purpose: as antiviral agent for COVID-19 and as of possible S.aureus superinfection.